We are live on ! Find out more
RDY icon

Dr. Reddy's Laboratories

169 hedge funds and large institutions have $1.12B invested in Dr. Reddy's Laboratories in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 23

3.11% more ownership

Funds ownership: 73.05%76.17% (+3.1%)

2% more funds holding

Funds holding: 165169 (+4)

4% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 53

3% more capital invested

Capital invested by funds: $1.09B → $1.12B (+$29.5M)

37% less call options, than puts

Call options by funds: $311K | Put options by funds: $496K

Holders
169
Holders Change
+4
Holders Change %
+2.42%
% of All Funds
4.86%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
27
Increased
55
Reduced
53
Closed
23
Calls
$311K
Puts
$496K
Net Calls
-$185K
Net Calls Change
-$1.08M
Name Holding Trade Value Shares
Change
Change in
Stake
Zurich Cantonal Bank
26
Zurich Cantonal Bank
Switzerland
$10.1M -$1.88M -223,350 -16%
SO
27
STRS Ohio
Ohio
$9.67M
RFC
28
Russell Frank Company
Washington
$9.66M +$4.55M +540,655 +100%
Legal & General Group
29
Legal & General Group
United Kingdom
$8.98M -$1.17M -139,695 -12%
State of New Jersey Common Pension Fund D
30
State of New Jersey Common Pension Fund D
New Jersey
$8.85M +$189K +22,420 +2%
Northern Trust
31
Northern Trust
Illinois
$8.85M +$613K +72,885 +8%
CCM
32
Causeway Capital Management
California
$8.41M -$9.69M -1,152,000 -54%
PPA
33
Parametric Portfolio Associates
Washington
$7.35M +$536K +63,795 +8%
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$7.21M +$672K +79,915 +11%
BIM
35
BlackRock Investment Management
Delaware
$6.71M -$184K -21,895 -3%
NG
36
NatWest Group
United Kingdom
$6.67M +$6.5M +772,675 New
SGA
37
Sector Gamma AS
Norway
$6.31M +$6.15M +730,760 New
BA
38
BlackRock Advisors
Delaware
$6.24M -$6.41M -762,390 -51%
STC
39
SEI Trust Company
Pennsylvania
$6.03M +$1.81M +215,505 +45%
HSBC Holdings
40
HSBC Holdings
United Kingdom
$6.01M +$4.93M +586,450 +530%
VAM
41
Visium Asset Management
New York
$5.84M +$5.69M +676,780 New
Deutsche Bank
42
Deutsche Bank
Germany
$5.55M +$40.3K +4,795 +0.8%
Allianz Asset Management
43
Allianz Asset Management
Germany
$5.43M -$1.18M -139,955 -18%
MFAM
44
Motley Fool Asset Management
Virginia
$5.39M
Lazard Asset Management
45
Lazard Asset Management
New York
$5.22M +$503K +59,820 +11%
AG
46
Aperio Group
California
$5.22M -$120K -14,270 -2%
BFA
47
BlackRock Fund Advisors
California
$5.15M -$11.3K -1,340 -0.2%
Principal Financial Group
48
Principal Financial Group
Iowa
$5.04M -$21.7M -2,585,130 -82%
U
49
UBS
Switzerland
$4.96M -$459K -54,630 -9%
Natixis Advisors
50
Natixis Advisors
Massachusetts
$4.25M +$4.14M +492,695 New

RDY Hedge Fund Activity: Q2 2014 in Review

169 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q2 2014, worth a combined $1.12B — up 2.7% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new RDY positions and 23 closed out — a net gain of 4 holders — while 55 added to existing stakes and 53 trimmed.

The largest buyer was Fisher Asset Management, adding an estimated $61M. The largest seller was Ninety One (UK), exiting entirely with an estimated $22.1M sold.

  • 169 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q2 2014, up from 165 in Q1 2014.
  • Funds reported $1.12B of Dr. Reddy's Laboratories stock for Q2 2014, up 2.7% quarter-over-quarter.
  • 27 funds opened new Dr. Reddy's Laboratories positions in Q2 2014 and 23 closed out, a net change of +4 holders.
  • The largest Dr. Reddy's Laboratories buyer in Q2 2014 was Fisher Asset Management, an estimated $61M added.
  • The largest Dr. Reddy's Laboratories seller in Q2 2014 was Ninety One (UK), an estimated $22.1M sold.

Based on aggregated 13F filings for Q2 2014.